PFBT
VKTX icon

Parkside Financial Bank & Trust’s Viking Therapeutics VKTX Stock Holding History

Parkside Financial Bank & Trust’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75.2K Buy
2,310
+7
+0.3% +$225 0.01% 801
2025
Q4 		$81K Buy
2,303
+52
+2% +$1.84K 0.01% 775
2025
Q3 		$59.2K Buy
2,251
+970
+76% +$28.9K ﹤0.01% 871
2025
Q2 		$33.9K Buy
1,281
+3
+0.2% +$79 ﹤0.01% 1028
2025
Q1 		$30.9K Buy
1,278
+404
+46% +$12.8K ﹤0.01% 988
2024
Q4 		$35.2K Sell
874
-5
-0.6% -$285 ﹤0.01% 918
2024
Q3 		$55.6K Buy
879
+5
+0.6% +$293 0.01% 746
2024
Q2 		$46.3K Buy
874
+39
+5% +$2.56K 0.01% 774
2024
Q1 		$68.5K Buy
835
+535
+178% +$23.8K 0.01% 640
2023
Q4 		$5.58K Hold
300
– – ﹤0.01% 1279
2023
Q3 		$3.32K Hold
300
– – ﹤0.01% 1510
2023
Q2 		$4.86K Buy
300
+100
+50% +$2.1K ﹤0.01% 1386
2023
Q1 		$3.33K Buy
+200
New +$2.07K ﹤0.01% 1514

Other funds holding VKTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Parkside Financial Bank & Trust's VKTX Position: Q1 2026 in Review

Parkside Financial Bank & Trust increased its Viking Therapeutics (VKTX) stake by 0.3% in Q1 2026, buying an estimated $225 and bringing the position to 2,310 shares worth $75.2K. The position accounts for 0.01% of the portfolio, ranked #801.

Parkside Financial Bank & Trust first reported a position in VKTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $81K in Q4 2025. 413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Parkside Financial Bank & Trust held 2,310 shares of Viking Therapeutics worth $75.2K as of Q1 2026.
  • Parkside Financial Bank & Trust bought 7 Viking Therapeutics shares in Q1 2026, an estimated $225.
  • Viking Therapeutics made up 0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #801 holding.
  • Parkside Financial Bank & Trust first reported a position in Viking Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Parkside Financial Bank & Trust's Viking Therapeutics position peaked at $81K in Q4 2025.
  • 413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.